Anacor Pharmaceuticals Down 14.4% After GlaxoSmithKline Pauses Ongoing Trials

Anacor Pharmaceuticals ANAC is down pre-market after the announcement that its partner GlaxoSmithKline GSK has voluntarily paused enrollment of ongoing GSK ‘052 phase 1 and 2 clinical trials. CEO of Anacor Pharmaceuticals, David Perry said: “We will work with GSK to better understand this microbiological finding, which we anticipate could take several months. We respect GSK's decision to pause enrollment in the current studies as we fully investigate the microbiology finding in the Phase 2b cUTI patients.” Anacor Pharmaceuticals is currently trading at $6.35, down $1.07 or 14.42% pre-market.